Target intelligence / Profile preview

Nucleic acid-sensing Toll-like receptors (TLR3, TLR7, TLR8, TLR9) (NA-TLRs)

Target
NA-TLRs
Molecular classification
Receptor, Pattern recognition receptor, Toll-like receptor family
01

Overview

Nucleic acid-sensing Toll-like receptors (TLRs), specifically TLR3, TLR7, TLR8, and TLR9, are endosomal receptors that play a pivotal role in the innate immune system by detecting foreign genetic material. TLR3 recognizes double-stranded RNA, TLR7 and TLR8 detect single-stranded RNA, and TLR9 identifies unmethylated CpG DNA motifs [Source: UniProt]. Upon activation, these receptors initiate signaling pathways that result in the production of type I interferons and other pro-inflammatory cytokines, which are essential for antiviral and antibacterial defense. However, the inappropriate recognition of self-nucleic acids by these receptors is strongly linked to the pathogenesis of autoimmune disorders like systemic lupus erythematosus and psoriasis [Source: PubMed, PMID: 30108117]. Therapeutic interventions often focus on blocking these pathways, either through direct receptor antagonism or via ligand sequestration. Ligand sequestration involves specialized molecules, such as cationic polymers or antibodies, that bind to and neutralize the nucleic acid ligands before they can trigger the receptors [Source: PNAS, doi:10.1073/pnas.1109096108]. This approach aims to reduce the inflammatory burden in chronic conditions without completely compromising the immune system's ability to respond to other threats. Drugs like hydroxychloroquine have long been used to modulate these pathways, while newer, more specific inhibitors are currently in clinical development.

Other names
Endosomal Toll-like receptorsNucleic acid-sensing TLRsTLR3/7/8/9
02

Mechanism of action

Inhibition of receptor activation through ligand sequestration (binding and neutralizing DNA/RNA) or direct competitive antagonism of the endosomal receptor binding sites [Source: Nature Reviews Immunology, doi:10.1038/nri.2017.115].

03

Biological functions

Immune responseSignal transductionCytokine productionAntiviral responseInnate immunity
04

Disease associations

Systemic lupus erythematosusPsoriasisRheumatoid arthritisSjogren's syndromeViral infectionCancer
05

Safety considerations

Increased susceptibility to viral infectionsSystemic immunosuppressionRetinal toxicityGastrointestinal distress
06

Interacting drugs

Hydroxychloroquine

4 more in the full profile.

07

Biomarkers

Type I Interferon (IFN-alpha)CXCL10 (IP-10)Interleukin-6 (IL-6)Anti-dsDNA antibodies

Beyond the preview

Go deeper on Nucleic acid-sensing Toll-like receptors (TLR3, TLR7, TLR8, TLR9) (NA-TLRs).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleic acid-sensing Toll-like receptors (TLR3, TLR7, TLR8, TLR9) (NA-TLRs).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call